SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
RNAi
An SI Board Since May 2003
Posts SubjectMarks Bans
671 52 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
221isis has a target validation partnership with atugen. any idea whether this woulbob zagorin-5/12/2004
220More from atugen, including quote and patent app number. Cheers, Thomas atugen Thomas-5/12/2004
219RNAi delivery achieved by atugen drugresearcher.com - 12/05/2004 - Germany’s Thomas-5/12/2004
218>>Published online before print April 30, 2004 Proc. Natl. Acad. Sci. USA,tuck-4/30/2004
217Research and Markets: RNAi Market: Estimated to be $300 million and Expected incbob zagorin-4/28/2004
216major section of the new Isis annual report focus on RNA... ir.thomsonfn.combob zagorin-4/26/2004
215>>LOS ANGELES, April 23 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdatuck-4/24/2004
214RNAi report models and quantifies the hype (for those who pony up for the reportThomas-4/22/2004
213[RNA interference microarrays: High-throughput loss-of-function genetics in mammtuck-4/20/2004
212Sirna's Nassim Ussman on RNAi therapeutics: currentdrugdiscovery.com Cheertuck-4/19/2004
211Another sceptical take on RNAI therapeutics - corante.comnigel bates-4/19/2004
210Hi Tuck & al, atugen, German spin-off of the Company f/k/a RZYM, now RNAI, jThomas-4/14/2004
209[siRNAS: Applications in functional genomics and potential as therapeutics] Nattuck-4/1/2004
208[Double knockdowns with retroviral delivery in mammalian cells] >>Publishtuck-3/30/2004
207Thanks, Tuck. Also appreciated the Scientist recap article. Look forward to heThomas-3/29/2004
206No thoughts beyond the article, no. Meanwhile, a team from the Lawrence Livermotuck-3/29/2004
205Economist article (from January) below. Any thoughts on the modeling of siRNA&#Thomas-3/29/2004
204The Scientist with a fresh overview of RNAi therapeutics. Downplays the interfetuck-3/28/2004
203Benitec Initiates Patent Infringement Lawsuit to Protect RNAi Gene Silencing Tecnigel bates-3/26/2004
202>>LOS ANGELES, March 23 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdatuck-3/23/2004
201<i>From the PNAS web site: pnas.org </i> The 50 Most-Frequently-Reatnsaf-3/22/2004
200atugen presenting at Sachs-Bloomberg in Boston. Sirna still owns a piece of atuThomas-3/22/2004
199Yet another siRNA conference: srinstitute.com Maybe the best near term play in Thomas-3/22/2004
198i looked at the insider sales at isis and i don't see what you mean. there wbob zagorin-3/19/2004
197>>LOS ANGELES, March 18 /PRNewswire-FirstCall/ -- Craig Mello, Ph.D., co- tuck-3/19/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News